Metrics, Inc.
MetricsInc.com
1240 Sugg Parkway, Greenville, NC 27834
Contact Information:
Jeff Basham, VP Sales & Marketing
jeff@metricsinc.com or 252-752-3800
Metrics Inc. is one of the most respected CDMOs in the US today. Our full range of services includes formulations development, commercial manufacturing, analytical methods development, First Time In Man, potent and cytotoxic drug handling, raw materials testing, trace metals testing and stability storage and testing.
Three critical differences set Metrics apart. One, clients work directly with a senior Metrics pharmaceutical scientist or analytical development chemist. Two, projects are expedited quickly and efficiently; they don’t languish in an analytical development queue, so timelines are met consistently. Three, Metrics’ quality assurance team is highly experienced, ensuring compliance with all regulatory issues.
Metrics is pleased to invite you to visit our booth #1119 at Interphex. To meet our team please contact Jeff Basham, VP of Sales and Marketing, at jeff@metricsinc.com or 252-752-3800.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.